The PRECISION Trial (Profiling Early Breast Cancer for Radiotherapy Omission): A Phase II Study of Breast-Conserving Surgery Without Adjuvant Radiotherapy for Favorable-Risk Breast Cancer

• ClinicalTrials.gov Identifier: NCT02653755
• Recruitment Status: Active, not recruiting
• First Posted: January 12, 2016
• Last Update Posted: April 24, 2024
• Sponsor: Dana-Farber Cancer Institute
• Collaborator: NanoString Technologies, Inc.
• Information provided by (Responsible Party): Jennifer Bellon, MD, Dana-Farber Cancer Institute

Study Description

Brief Summary:

This research study is a way of gaining new knowledge about whether patients can omit radiation treatment after undergoing a lumpectomy, also known as "breast conserving surgery". In this trial, we are attempting to identify which patients may not need radiation.

Condition or disease	Intervention/treatment	Phase
Breast Cancer Radiation	Device: Prosigna	Phase 2

Detailed Description:

This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational treatment to learn whether it is appropriate for treating a specific disease.

The purpose of this study is to determine whether certain patients between the ages of 50 and 75 can safely omit radiation treatment after having a lumpectomy.In this research study, the investigators are using standard laboratory tests along with the Prosigna test to see if certain patients can avoid radiation, without having a higher risk of the cancer coming back in the future.

A portion of the participant surgical specimen will be prospectively maintained for future study using institutionally-approved tissue banking procedures.

The FDA (the U.S. Food and Drug Administration) has cleared the Prosigna test for generating a risk category and numerical score to assess the risk of distant recurrence, and has cleared us to investigate the use of the Prosigna test for helping with decisions about radiation.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 671 participants
• Allocation: Non-Randomized
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: The PRECISION Trial (Profiling Early Breast Cancer for Radiotherapy Omission): A Phase II Study of Breast-Conserving Surgery Without Adjuvant Radiotherapy for Favorable-Risk Breast Cancer
• Study Start Date: May 2016
• Estimated Primary Completion Date: December 2025
• Estimated Study Completion Date: June 2026

Arms and Interventions

Arm	Intervention/treatment
Active Comparator: Ineligible for omission of RT; Prosigna confirms intermediate- or high-risk score. Participants with intermediate- or high-risk scores will be ineligible for omission of radiotherapy (RT). Some patients with low-risk scores may elect to receive RT.	Device: Prosigna; Transcriptional profile of 50 genes used for risk stratification.; Other Name: PAM-50
Active Comparator: Eligible for omission of RT; Prosigna confirms low risk score. Participant will be eligible for omission of therapy and chooses to do so. Patient will receive adjuvant endocrine therapy.	Device: Prosigna; Transcriptional profile of 50 genes used for risk stratification.; Other Name: PAM-50

Outcome Measures

Primary Outcome Measures :

1. Five-Year Risk of Local Regional Recurrence in the Ipsilateral Breast or Lymph Nodes in Women without Adjuvant Radiotherapy [ Time Frame: 5 years ]
   Using information gathered from follow-up physical examinations and mammography, the 5-year risk of local regional recurrence in women who omit radiotherapy post-lumpectomy will be evaluated.

Secondary Outcome Measures :

1. Five-Year Risk of Any Recurrence: Local, Regional or Distant [ Time Frame: 5 years ]
   Using information gathered from follow-up physical examinations and mammography, the 5-year risk of any recurrence in women who omit radiotherapy post-lumpectomy will be evaluated.
2. Overall Survival [ Time Frame: 5 years ]
   Using information gathered from follow-up appointments and other record sources, 5-year survival rates will be evaluated.
3. Disease-Free Survival [ Time Frame: 5 years ]
   Using information gathered from follow-up physical exams, mammography and other imaging as necessary, the rate of disease-free status at 5 years will be evaluated.

Eligibility Criteria

• Ages Eligible for Study: 50 Years to 75 Years (Adult, Older Adult)
• Sexes Eligible for Study: Female
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Histologically confirmed invasive breast cancer
• The primary tumor must be excised via breast conserving surgery ("lumpectomy") with negative margins ("no ink on tumor") or re-excision showing no residual disease in the re-excision specimen.
• The tumor must be ≤2 cm (T1) in the largest dimension.
• Immunohistochemical studies must demonstrate the tumor to be ER+ (≥10%) or PR+, HER2- and grade 1 or 2.
• The patient must have undergone either sentinel lymph node biopsy (SLNB) or axillary lymph node dissection (ALND) demonstrating pathologic node-negativity (pN0). However, patients with immunohistochemical evidence of isolated tumor cells in a lymph node [pN0(i+)] are eligible if no deposit >0.2mm is identified.
• Age: this study is open to patients between 50 and 75 years of age (inclusive). Patients younger than 50 years of age are excluded based on prior data suggesting a different natural history for breast cancers arising in premenopausal women (with different subtype and biologic distributions that may confound the current aims). Women older than 75 years of age are excluded from this protocol due to historical difficulties achieving robust follow-up in this population, along with competing comorbidities which have been shown to interfere with subsequent breast cancer monitoring and evaluation.
• ECOG performance status ≤2 (Karnofsky ≥60%)
• Life expectancy of >5 years per the clinical impression of the treating physician(s).
• Eligible for and willing to undergo a course of adjuvant endocrine therapy.

Exclusion Criteria:

• At the time of enrollment, subjects may not have had any prior systemic therapy for breast cancer, including chemotherapy, hormonal therapy or targeted biologic therapy. Similarly, chemotherapy or biologic therapy must not be part of the subsequent treatment plan.
• Clinical, radiographic or pathologic evidence of multicentric disease.
• Evidence of T4 disease (e.g., involvement of the chest wall, skin, dermal lymphatics, or inflammatory breast cancer).
• Grade 3 histology.
• Tumors in which the invasive component is present only as micro-invasion.
• Multicentric invasive or in site carcinoma
• Bilateral breast malignancy.
• Inability or unwillingness to tolerate endocrine therapy.
• Documented mutation of TP53, BRCA1, BRCA2, or other hereditary cancer syndromes.
• Significant comorbidity associated with an estimation of <5 remaining life years.
• Another diagnosis of malignancy within the 5 years preceding enrollment (excluding non-melanoma skin cancers or in situ cervical lesions, which are permitted).
• Inability to understand or provide informed consent.
• Current addictive or psychiatric disorder which may preclude protocol adherence.
• Prior breast or chest radiotherapy for any indication.
• Pregnant or lactating.

Contacts and Locations

Locations

United States, Maryland

Johns Hopkins

Baltimore, Maryland, United States, 21287

United States, Massachusetts

Massachusetts General Hospital

Boston, Massachusetts, United States, 02114

Dana-Farber Cancer Institute

Boston, Massachusetts, United States, 02115

United States, New York

NYU Langone Health

New York, New York, United States, 10016

Memorial Sloane Kettering Cancer Center

New York, New York, United States, 10065

United States, Rhode Island

Lifespan Cancer Institute

Providence, Rhode Island, United States, 02903

Sponsors and Collaborators

Dana-Farber Cancer Institute

NanoString Technologies, Inc.

Investigators

• Principal Investigator: Jennifer Bellon, MD; Dana-Farber Cancer Institute

More Information

• Responsible Party: Jennifer Bellon, MD, Jennifer Bellon MD, Dana-Farber Cancer Institute
• ClinicalTrials.gov Identifier: NCT02653755
• Other Study ID Numbers: 15-255
• First Posted: January 12, 2016
• Last Update Posted: April 24, 2024
• Last Verified: April 2024

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

Keywords provided by Jennifer Bellon, MD, Dana-Farber Cancer Institute:

Breast Cancer Radiation; Radiotherapy for Favorable-Risk Breast cancer; Radiotherapy Omission

Additional relevant MeSH terms:

Breast Neoplasms; Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases